{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:04:30Z","timestamp":1789553070639,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    TSC\/mTOR pathway alteration is recurrent in numerous renal tumor types, such as eosinophilic vacuolated tumor (EVT), low-grade oncocytic tumor of the kidney (LOT), and eosinophilic solid and cystic (ESC) renal cell carcinoma (RCC). Recently, additional renal tumor types with recurrent TSC\/mTOR pathway mutation, such as xanthomatous giant cell RCC and RCC with leiomyomatous stroma, have also been described, further expanding the spectrum of renal tumors with TSC\/mTOR pathway mutation. To this date, most renal tumors with TSC\/mTOR pathway mutation are reported to be mostly indolent, with only rare cases of metastasis. However, this report describes two cases (one of which was previously published as a case report) of\n                    <jats:italic>MTOR<\/jats:italic>\n                    -mutated eosinophilic RCCs with loss of chromosome 1. The tumors mostly exhibit solid\/nested and sheet-like growth patterns composed of tumor cells with plump eosinophilic cytoplasm, with occasional vacuolation, pronounced cellular membrane, and occasional perinuclear clearing. The tumor cells showed prominent nucleoli and round nuclei with smooth nuclear membrane. The tumor had occasional binucleated tumor cells with rhabdoid morphology, areas with prominent hyalinized stroma and psammomatous calcification, and tumor cells with blue granules. Immunohistochemistry showed that the tumors were diffusely positive for CD117 and negative for vimentin, and negative for CK7, Melan A, and TFE3. CK20 was positive in both tumors, with diffuse expression in one and focal expression in the other. Next-generation sequencing showed concomitant\n                    <jats:italic>MTOR<\/jats:italic>\n                    mutation and loss of chromosome 1. Both tumors displayed metastatic potential. Overall, these\n                    <jats:italic>MTOR<\/jats:italic>\n                    -mutated eosinophilic RCCs with loss of chromosome 1 have distinct morphologic, immunohistochemical, and molecular features as well as high metastatic potential, further expanding the spectrum of TSC\/mTOR pathway-mutated renal tumors. This tumor requires further investigations due to its high metastatic potential that is infrequently observed in other TSC\/mTOR pathway-mutated renal tumors and the potential therapeutic target it may offer in mTOR inhibitor.\n                  <\/jats:p>","DOI":"10.1007\/s00428-025-04363-4","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T03:37:21Z","timestamp":1764214641000},"page":"575-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MTOR-mutated eosinophilic renal cell carcinomas with loss of chromosome 1 and high metastatic potential: further expanding the spectrum of TSC\/mTOR pathway mutated\u00a0renal tumors"],"prefix":"10.1007","volume":"489","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1793-2732","authenticated-orcid":false,"given":"Jung Woo","family":"Kwon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa Y.","family":"Tjota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0455-9413","authenticated-orcid":false,"given":"Tatjana","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4363_CR1","doi-asserted-by":"publisher","unstructured":"Farca\u015f M, Gatalica Z, Trpkov K et al (2021) Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC\/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases [published correction appears in Mod Pathol. 34(12):2243. https:\/\/doi.org\/10.1038\/s41379-021-00941-4] [published correction appears in Mod Pathol. 2022 Feb;35(2):289. https:\/\/doi.org\/10.1038\/s41379-021-00941-4]. Mod Pathol. 2022;35(3):344\u2013351. https:\/\/doi.org\/10.1038\/s41379-021-00923-6","DOI":"10.1038\/s41379-021-00941-4"},{"issue":"4","key":"4363_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/PAP.0000000000000299","volume":"28","author":"P Kapur","year":"2021","unstructured":"Kapur P, Gao M, Zhong H et al (2021) Eosinophilic vacuolated tumor of the kidney: a review of evolving concepts in this novel subtype with additional insights from a case with MTOR mutation and concomitant chromosome 1 loss. Adv Anat Pathol 28(4):251\u2013257. https:\/\/doi.org\/10.1097\/PAP.0000000000000299","journal-title":"Adv Anat Pathol"},{"issue":"11","key":"4363_CR3","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1097\/PAS.0000000000001955","volume":"46","author":"QY Xia","year":"2022","unstructured":"Xia QY, Wang XT, Zhao M et al (2022) TSC\/MTOR-associated eosinophilic renal tumors exhibit a heterogeneous clinicopathologic spectrum\u202f: a targeted next-generation sequencing and gene expression profiling study. Am J Surg Pathol 46(11):1562\u20131576. https:\/\/doi.org\/10.1097\/PAS.0000000000001955","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"4363_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00428-018-2456-4","volume":"473","author":"H He","year":"2018","unstructured":"He H, Trpkov K, Martinek P et al (2018) \u201cHigh-grade oncocytic renal tumor\u201d: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch 473(6):725\u2013738. https:\/\/doi.org\/10.1007\/s00428-018-2456-4","journal-title":"Virchows Arch"},{"issue":"1","key":"4363_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/PAS.0000000000001170","volume":"43","author":"YB Chen","year":"2019","unstructured":"Chen YB, Mirsadraei L, Jayakumaran G et al (2019) Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol 43(1):121\u2013131. https:\/\/doi.org\/10.1097\/PAS.0000000000001170","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"4363_CR6","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/PAS.0000000000001457","volume":"44","author":"M Tjota","year":"2020","unstructured":"Tjota M, Chen H, Parilla M, Wanjari P, Segal J, Antic T (2020) Eosinophilic renal cell tumors with a TSC and MTOR gene mutations are morphologically and immunohistochemically heterogenous: clinicopathologic and molecular study. Am J Surg Pathol 44(7):943\u2013954. https:\/\/doi.org\/10.1097\/PAS.0000000000001457","journal-title":"Am J Surg Pathol"},{"key":"4363_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.humpath.2020.12.006","volume":"115","author":"MY Tjota","year":"2021","unstructured":"Tjota MY, Wanjari P, Segal J, Antic T (2021) TSC\/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+\/CK20-\/vimentin-: a validation study. Hum Pathol 115:84\u201395. https:\/\/doi.org\/10.1016\/j.humpath.2020.12.006","journal-title":"Hum Pathol"},{"issue":"5","key":"4363_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00428-022-03283-x","volume":"480","author":"HZ Zhang","year":"2022","unstructured":"Zhang HZ, Xia QY, Wang SY, Shi MJ, Wang SY (2022) Low-grade oncocytic tumor of kidney harboring TSC\/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity. Virchows Arch 480(5):999\u20131008. https:\/\/doi.org\/10.1007\/s00428-022-03283-x","journal-title":"Virchows Arch"},{"key":"4363_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.humpath.2021.04.013","volume":"114","author":"O Kravtsov","year":"2021","unstructured":"Kravtsov O, Gupta S, Cheville JC et al (2021) Low-grade oncocytic tumor of kidney (CK7-positive, CD117-negative): incidence in a single institutional experience with clinicopathological and molecular characteristics. Hum Pathol 114:9\u201318. https:\/\/doi.org\/10.1016\/j.humpath.2021.04.013","journal-title":"Hum Pathol"},{"issue":"3","key":"4363_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/s41379-021-00906-7","volume":"35","author":"A Morini","year":"2022","unstructured":"Morini A, Drossart T, Timsit MO et al (2022) Low-grade oncocytic renal tumor (LOT): mutations in MTOR pathway genes and low expression of FOXI1. Mod Pathol 35(3):352\u2013360. https:\/\/doi.org\/10.1038\/s41379-021-00906-7","journal-title":"Mod Pathol"},{"issue":"3","key":"4363_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41379-021-00969-6","volume":"35","author":"SK Mohanty","year":"2022","unstructured":"Mohanty SK, Satapathy A, Aggarwal A et al (2022) Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway. Mod Pathol 35(3):361\u2013375. https:\/\/doi.org\/10.1038\/s41379-021-00969-6","journal-title":"Mod Pathol"},{"issue":"3","key":"4363_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41379-021-00896-6","volume":"35","author":"P Kapur","year":"2022","unstructured":"Kapur P, Gao M, Zhong H et al (2022) Germline and sporadic MTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol 35(3):333\u2013343. https:\/\/doi.org\/10.1038\/s41379-021-00896-6","journal-title":"Mod Pathol"},{"issue":"2","key":"4363_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/his.14816","volume":"82","author":"SR Williamson","year":"2023","unstructured":"Williamson SR, Hes O, Trpkov K et al (2023) Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. Histopathology 82(2):296\u2013304. https:\/\/doi.org\/10.1111\/his.14816","journal-title":"Histopathology"},{"issue":"4","key":"4363_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.eururo.2018.06.007","volume":"74","author":"R Mehra","year":"2018","unstructured":"Mehra R, Vats P, Cao X et al (2018) Somatic bi-allelic loss of TSC genes in eosinophilic solid and cystic renal cell carcinoma. Eur Urol 74(4):483\u2013486. https:\/\/doi.org\/10.1016\/j.eururo.2018.06.007","journal-title":"Eur Urol"},{"issue":"3","key":"4363_CR15","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41379-021-00816-8","volume":"35","author":"E Munari","year":"2022","unstructured":"Munari E, Settanni G, Cali\u00f2 A et al (2022) TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. Mod Pathol 35(3):376\u2013385. https:\/\/doi.org\/10.1038\/s41379-021-00816-8","journal-title":"Mod Pathol"},{"issue":"12","key":"4363_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/PAS.0000000000002101","volume":"47","author":"P Argani","year":"2023","unstructured":"Argani P, Medeiros LJ, Matoso A et al (2023) Oncocytoid renal cell carcinomas after neuroblastoma\" represent TSC -mutated eosinophilic solid and cystic renal cell carcinomas\u202f: association with prior childhood malignancy and multifocality with therapeutic implications. Am J Surg Pathol 47(12):1335\u20131348. https:\/\/doi.org\/10.1097\/PAS.0000000000002101","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"4363_CR17","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/PAS.0000000000000508","volume":"40","author":"K Trpkov","year":"2016","unstructured":"Trpkov K, Hes O, Bonert M et al (2016) Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol 40(1):60\u201371. https:\/\/doi.org\/10.1097\/PAS.0000000000000508","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"4363_CR18","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/PAS.0000000000001111","volume":"42","author":"DN Palsgrove","year":"2018","unstructured":"Palsgrove DN, Li Y, Pratilas CA et al (2018) Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum. Am J Surg Pathol 42(9):1166\u20131181. https:\/\/doi.org\/10.1097\/PAS.0000000000001111","journal-title":"Am J Surg Pathol"},{"key":"4363_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/10668969241291885","author":"JW Kwon","year":"2024","unstructured":"Kwon JW, Nguyen TD, Tjota MY, Antic T (2024) GATA3 expression in solid vimentin-negative eosinophilic renal epithelial tumors-a comprehensive study of 48 tumors. Int J Surg Pathol. https:\/\/doi.org\/10.1177\/10668969241291885","journal-title":"Int J Surg Pathol"},{"key":"4363_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1610852","volume":"29","author":"T Chen","year":"2023","unstructured":"Chen T, Peng Y, Lei T, Wu C, Wang H, Shi Y (2023) Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations. Pathol Oncol Res 29:1610852. https:\/\/doi.org\/10.3389\/pore.2023.1610852","journal-title":"Pathol Oncol Res"},{"key":"4363_CR21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.humpath.2018.05.023","volume":"80","author":"MS Tretiakova","year":"2018","unstructured":"Tretiakova MS (2018) Eosinophilic solid and cystic renal cell carcinoma mimicking epithelioid angiomyolipoma: series of 4 primary tumors and 2 metastases. Hum Pathol 80:65\u201375. https:\/\/doi.org\/10.1016\/j.humpath.2018.05.023","journal-title":"Hum Pathol"},{"issue":"22","key":"4363_CR22","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.12998\/wjcc.v12.i22.5124","volume":"12","author":"HH Cao","year":"2024","unstructured":"Cao HH, Li H, Guo XH, Cao ZX, Zhang BH (2024) Eosinophilic solid and cystic renal cell carcinoma with aggressive behavior: two case reports. World J Clin Cases 12(22):5124\u20135130. https:\/\/doi.org\/10.12998\/wjcc.v12.i22.5124","journal-title":"World J Clin Cases"},{"issue":"4","key":"4363_CR23","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/his.13395","volume":"72","author":"Y Li","year":"2018","unstructured":"Li Y, Reuter VE, Matoso A, Netto GJ, Epstein JI, Argani P (2018) Re-evaluation of 33 \u201cunclassified\u201d eosinophilic renal cell carcinomas in young patients. Histopathology 72(4):588\u2013600. https:\/\/doi.org\/10.1111\/his.13395","journal-title":"Histopathology"},{"issue":"11","key":"4363_CR24","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1097\/PAS.0000000000001940","volume":"46","author":"P Argani","year":"2022","unstructured":"Argani P, Matoso A, Pallavajjalla A et al (2022) Xanthomatous giant cell renal cell carcinoma: another morphologic form of TSC -associated renal cell carcinoma. Am J Surg Pathol 46(11):1554\u20131561. https:\/\/doi.org\/10.1097\/PAS.0000000000001940","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"4363_CR25","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/PAS.0000000000002215","volume":"48","author":"Y Xu","year":"2024","unstructured":"Xu Y, Zhang X, Xia Q et al (2024) Clinicopathologic and molecular characterization of xanthomatous giant cell renal cell carcinomas: further support for a close morphologic spectrum to eosinophilic solid and cystic renal cell carcinomas. Am J Surg Pathol 48(6):662\u2013670. https:\/\/doi.org\/10.1097\/PAS.0000000000002215","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"4363_CR26","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.pathol.2020.10.013","volume":"53","author":"MY Tjota","year":"2021","unstructured":"Tjota MY, Segal J, Stadler WM, Antic T (2021) Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case. Pathology 53(6):790\u2013793. https:\/\/doi.org\/10.1016\/j.pathol.2020.10.013","journal-title":"Pathology"},{"issue":"6","key":"4363_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00428-023-03688-2","volume":"483","author":"A Cali\u00f2","year":"2023","unstructured":"Cali\u00f2 A, Marletta S, Settanni G et al (2023) mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy. Virchows Arch 483(6):821\u2013833. https:\/\/doi.org\/10.1007\/s00428-023-03688-2","journal-title":"Virchows Arch"},{"issue":"1","key":"4363_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","volume":"19","author":"S Kadri","year":"2017","unstructured":"Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV, Segal JP (2017) Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J Mol Diagn 19(1):43\u201356. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.07.012","journal-title":"J Mol Diagn"},{"key":"4363_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105680","volume":"153","author":"S Gupta","year":"2024","unstructured":"Gupta S, McCarthy MR, Tjota MY, Antic T, Cheville JC (2024) Metastatic renal cell carcinoma with fibromyomatous stroma associated with tuberous sclerosis or MTOR, TSC1\/TSC2-mutations: a series of 4 cases and a review of the literature. Hum Pathol 153:105680. https:\/\/doi.org\/10.1016\/j.humpath.2024.105680","journal-title":"Hum Pathol"},{"key":"4363_CR30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.humpath.2022.12.015","volume":"134","author":"MY Tjota","year":"2023","unstructured":"Tjota MY, Sharma A, Wanjari P, Fitzpatrick C, Segal J, Antic T (2023) TSC\/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol 134:124\u2013133. https:\/\/doi.org\/10.1016\/j.humpath.2022.12.015","journal-title":"Hum Pathol"},{"issue":"5","key":"4363_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/PAS.0000000000001422","volume":"44","author":"RB Shah","year":"2020","unstructured":"Shah RB, Stohr BA, Tu ZJ et al (2020) Renal cell carcinoma with leiomyomatous stroma\" harbor somatic mutations of TSC1, TSC2, MTOR, and\/or ELOC (TCEB1): clinicopathologic and molecular characterization of 18 sporadic tumors supports a distinct entity. Am J Surg Pathol 44(5):571\u2013581. https:\/\/doi.org\/10.1097\/PAS.0000000000001422","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"4363_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00428-020-02910-9","volume":"478","author":"M Gournay","year":"2021","unstructured":"Gournay M, Dugay F, Belaud-Rotureau MA et al (2021) Renal cell carcinoma with leiomyomatous stroma in tuberous sclerosis complex: a distinct entity. Virchows Arch 478(4):793\u2013799. https:\/\/doi.org\/10.1007\/s00428-020-02910-9","journal-title":"Virchows Arch"},{"issue":"8","key":"4363_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/PAS.0000000000001255","volume":"43","author":"M Parilla","year":"2019","unstructured":"Parilla M, Alikhan M, Al-Kawaaz M, Patil S, Kadri S, Ritterhouse LL, Segal J, Fitzpatrick C, Antic T (2019) Genetic underpinnings of renal cell carcinoma with leiomyomatous stroma. Am J Surg Pathol 43(8):1135\u20131144. https:\/\/doi.org\/10.1097\/PAS.0000000000001255","journal-title":"Am J Surg Pathol"},{"issue":"269","key":"4363_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci Signal"},{"issue":"5","key":"4363_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04363-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04363-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:23:25Z","timestamp":1789550605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04363-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4363"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04363-4","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yes.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}